Australia markets close in 4 hours 4 minutes

Unity Biotechnology, Inc. (UBX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
6.13-0.60 (-8.92%)
At close: 4:00PM EST

Unity Biotechnology, Inc.

285 East Grand Avenue
South San Francisco, CA 94080
United States
650 416 1192

Full-time employees76

Key executives

NameTitlePayExercisedYear born
Dr. Nathaniel E. DavidCo-Founder & Exec. Director640.86kN/A1968
Dr. Anirvan GhoshCEO & DirectorN/AN/A1964
Dr. Jan M. van DeursenFounderN/AN/AN/A
Dr. Judith CampisiFounderN/AN/AN/A
Mr. Daohong Zhou M.D.FounderN/AN/AN/A
Ms. Lynne Marie SullivanChief Financial OfficerN/AN/A1966
Mr. Nathan Guz Ph.D.VP of OperationsN/AN/AN/A
Mr. Alexander AzoyVP of Fin., Chief Accounting Officer, Controller & Principal Accounting OfficerN/AN/A1976
Dr. Przemyslaw Sapieha Ph.D.Chief Scientific AdvisorN/AN/AN/A
Ms. Susan Lundeen SmuckChief HR OfficerN/AN/A1968
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase II clinical trial for musculoskeletal/ osteoarthritis disease, as well as Phase Ib clinical trial for moderate-to-severe osteoarthritis of the knee; UBX1325, which is Phase I clinical trial for the treatment of diabetic macular edema; and UBX1967 for the treatment of ophthalmologic diseases. It is also developing programs in pulmonary disorders and neurological disorders, as well as kidney and liver diseases. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in South San Francisco, California.

Corporate governance

Unity Biotechnology, Inc.’s ISS governance QualityScore as of 3 December 2020 is 9. The pillar scores are Audit: 6; Board: 9; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.